Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 11/20 | 0.51 |
| ▸ | HTR7 | P34969 | 8/20 | 0.51 |
| ▸ | DRD2 | P14416 | 11/20 | 0.48 |
| ▸ | HTR6 | P50406 | 4/20 | 0.46 |
| ▸ | DRD3 | P35462 | 5/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | SMYD2 | Q9NRG4 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | DRD5 | P21918 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL83163 | 0.78 | HTR1A (0.63) | HTR1AHTR7DRD2HTR6DRD3 | |
| SCHEMBL81701 | 0.74 | NAMPT (0.55) | — | |
| SCHEMBL3092994 | 0.73 | NAMPT (0.43) | — | |
| SCHEMBL3079533 | 0.72 | HTR1A (0.56) | HTR1AHTR7DRD2HTR6DRD3 | |
| SCHEMBL82842 | 0.72 | DRD2 (0.73) | HTR1ADRD2DRD3DRD4 | |
| SCHEMBL3074410 | 0.72 | DRD2 (0.73) | HTR1ADRD2DRD3DRD4 | |
| SCHEMBL3086811 | 0.72 | DRD2 (0.72) | HTR1ADRD2DRD3DRD4 | |
| SCHEMBL82749 | 0.72 | DRD2 (0.72) | HTR1ADRD2DRD3DRD4 | |
| SCHEMBL3073890 | 0.72 | DRD2 (0.72) | HTR1ADRD2DRD3DRD4 | |
| SCHEMBL82104 | 0.72 | DRD2 (0.72) | HTR1ADRD2DRD3DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4607319-B2 | — | — | 2011-01-05 | — | — | JP | claimed |
| US-20100227896-A1 | USE OF VITAMIN PP COMPOUNDS | ASTELLAS DEUTSCHLAND GMBH (DE) | 2010-09-09 | — | — | US | claimed |
| EP-1079832-B1 | USE OF VITAMIN PP COMPOUNDS | KLINGE CO CHEM PHARM FAB (DE) | 2005-11-30 | — | — | EP | claimed |
| JP-2002512190-A | — | — | 2002-04-23 | — | — | JP | claimed |
| EP-1079832-A1 | USE OF VITAMIN PP COMPOUNDS | Klinge Pharma GmbH (DE) | 2001-03-07 | — | — | EP | claimed |
| WO-1999053920-A1 | USE OF VITAMIN PP COMPOUNDS | KLINGE PHARMA GMBH (DE) | 1999-10-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227896-A1 | USE OF VITAMIN PP COMPOUNDS | PNPO, NAMPT, NAPRT | HTR1A 3335/4885HTR7 3976/4885DRD2 4023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.